{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:01:26Z","timestamp":1790017286332,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,21]]},"DOI":"10.7759\/cureus.116658","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:11:06Z","timestamp":1790014266000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment-Resistant Psychosis in an Adolescent at Risk of Metabolic Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Michael","family":"Belkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes OD","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, et al.. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017, 174:216-29. 10.1176\/appi.ajp.2016.16050503","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","volume":"220","author":"Siskind D","year":"2022","unstructured":"Siskind D, Orr S, Sinha S, et al.. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022, 220:115-20. 10.1192\/bjp.2021.61","journal-title":"Br J Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.02.008","article-title":"Practice parameter for the assessment and treatment of children and adolescents with schizophrenia","volume":"52","author":"McClellan J","year":"2013","unstructured":"McClellan J, Stock S. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013, 52:976-90. 10.1016\/j.jaac.2013.02.008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717720197","article-title":"Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth","volume":"62","author":"Abidi S","year":"2017","unstructured":"Abidi S, Mian I, Garcia-Ortega I, et al.. Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth. Can J Psychiatry. 2017, 62:635-47. 10.1177\/0706743717720197","journal-title":"Can J Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2007.00271.x","article-title":"The metabolic syndrome in children and adolescents - an IDF consensus report","volume":"8","author":"Zimmet P","year":"2007","unstructured":"Zimmet P, Alberti KG, Kaufman F, et al.. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007, 8:299-306. 10.1111\/j.1399-5448.2007.00271.x","journal-title":"Pediatr Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1014540","article-title":"Treatment resistant psychosis in children and adolescents and clozapine: Nuances","volume":"14","author":"Pattnaik JI","year":"2023","unstructured":"Pattnaik JI, Panda UK, Chandran S, Padhy S, Ravan JR. Treatment resistant psychosis in children and adolescents and clozapine: Nuances. Front Psychiatry. 2023, 14:10.3389\/fpsyt.2023.1014540","journal-title":"Front Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004027.pub2","article-title":"Antipsychotic medication for childhood-onset schizophrenia","volume":"2007","author":"Kennedy E","year":"2007","unstructured":"Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev. 2007, 2007:10.1002\/14651858.CD004027.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study","volume":"165","author":"Sikich L","year":"2008","unstructured":"Sikich L, Frazier JA, McClellan J, et al.. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008, 165:1420-31. 10.1176\/appi.ajp.2008.08050756","journal-title":"Am J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830120020005","article-title":"Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison","volume":"53","author":"Kumra S","year":"1996","unstructured":"Kumra S, Frazier JA, Jacobsen LK, et al.. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996, 53:1090-7. 10.1001\/archpsyc.1996.01830120020005","journal-title":"Arch Gen Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0092","article-title":"Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis","volume":"32","author":"Adnan M","year":"2022","unstructured":"Adnan M, Motiwala F, Trivedi C, Sultana T, Mansuri Z, Jain S. Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol. 2022, 32:2-11. 10.1089\/cap.2021.0092","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll CU","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009, 302:1765-73. 10.1001\/jama.2009.1549","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0416-8","article-title":"Therapeutic use of metformin in prediabetes and diabetes prevention","volume":"75","author":"Hostalek U","year":"2015","unstructured":"Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015, 75:1071-94. 10.1007\/s40265-015-0416-8","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1998.tb00314.x","article-title":"Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes","volume":"6","author":"Lee A","year":"1998","unstructured":"Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998, 6:47-53. 10.1002\/j.1550-8528.1998.tb00314.x","journal-title":"Obes Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"de Silva VA","year":"2016","unstructured":"de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016, 16:341. 10.1186\/s12888-016-1049-5","journal-title":"BMC Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen JR","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MS, et al.. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017, 74:719-28. 10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/535069-treatment-resistant-psychosis-in-an-adolescent-at-risk-of-metabolic-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:11:07Z","timestamp":1790014267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/535069-treatment-resistant-psychosis-in-an-adolescent-at-risk-of-metabolic-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.116658","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}